There is very little scientific evidence on components of cannabis other than cannabidiol or THC. These include cannabigerol (CBG) or cannabichromene (CBC). It becomes difficult to comprehend their benefits due to lack of enough insight on the subjects. It is not surprising that they can potentially benefit as efficient pharmaceutical active compounds.
Current standing of the market in understanding the role of other active ingredients
According to experts, the current market is not in favor of advocating any compounds of cannabis other than THC and CBD. However, there is ample room for funding for research once the US government legalizes it on a federal scale. Pharmaceutical companies are more likely to invest their dollars on finding the benefits of the active compounds. This is a good opportunity for them to make good profits.
On the other side, few production units and extracting brands and units like MediPharm Labs and Valens GroWorks are doing the job. They are incorporating the active ingredients of cannabis into making edibles, concentrates, serums, lotions, and ingestibles at the end of the year.
Published: May 24, 2019
Founder & Interim Editor of L.A. Cannabis News